The benchmark STOXX index was on track for its fourth consecutive session of record gains, as well as a sixth straight weekly rise, its longest such streak since March 2024.

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

Novartis AG’s plan to sell its 70.6% stake in Novartis India is on track, CEO Vas Narasimhan confirmed at the World Economic Forum in Davos. Speaking to CNBC-TV18, he emphasised the company’s ...

Greece on Monday prosecuted a pair of protected witnesses for alleged perjury in a long-running bribery probe involving the Swiss pharmaceutical firm Novartis, a justice source said. The man and woman ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto, per a ...

Entresto’s importance to Novartis is illustrated in the company’s most recent quarterly report, which revealed that the drug generated $5.6 billion in the first three quarters of 2024 ...

Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto. Novartis on Thursday secured a last ...

Novartis AG is challenging a federal health agency’s decision to rejects its proposal to discount drugs as a rebate rather than up-front to health providers that treat lower-income and uninsured ...

ONS-5010/LYTENAVA (bevacizumab gamma) has been approved in the European Union and the United Kingdom. Outlook Therapeutics intends to begin launching in Europe in the first half of calendar 2025.

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug ...

WASHINGTON, Jan 16 - Novartis (NOVN.S), opens new tab won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals from launching a generic ...